VRNA Verona Pharma plc Insider Trading

CMO Kathleen A. Rickard sold 58,336 shares of VRNA at $13.14 on 2025-08-01; stock has surged 52.4% in 90 days post-trade.

Rickard Kathleen A., Chief Medical Officer, disposed of 58,336 shares (2.2% of pre-transaction holdings) at $13.14 on 2025-08-01, raising $766,750.88. The timing of this sale merits attention: VRNA has gained 52.4% over the 90 days following the transaction, and 15.2% in the 30 days immediately after. Across her prior three sales at VRNA, this insider's track record shows average 90-day returns of +1,095.6%, with 0 of 3 prior sells being well-timed by the metric that a sell is well-timed only if the stock falls afterward. The company remains unprofitable (net income $-16,319,000.00 for the latest quarter) despite generating $76,256,000.00 in quarterly revenue. The large post-transaction price appreciation relative to the $13.14 sale price suggests the insider may have exited ahead of a sustained rally, though her historical timing pattern at this ticker shows no evidence of predictive accuracy in identifying declines after sales.

VRNA CEO David Zaccardelli sold 208,912 shares at $13.14 on 2025-08-01; stock rose +52.4% in 90 days post-transaction.

David Zaccardelli, President and CEO, sold 208,912 shares (208.9K shares) of Verona Pharma at $13.14, representing a 1.5% reduction in his 13.38M-share post-transaction holdings. The transaction occurred when the stock subsequently posted a 90-day return of +52.4%, indicating the sale was poorly timed relative to near-term price appreciation. Across his prior trades at VRNA (5 distinct transactions), his same-ticker timing shows 0 of 1 measurable 90-day outcomes were well-timed, and his cross-ticker track record reflects a 0.00% well-timed rate across 20 prior sells, suggesting a consistent pattern of selling before rallies rather than before declines. The company remains unprofitable (net income of $-16.3M on $76.3M revenue in the latest quarter), but the CEO's small relative share reduction and the stock's strong momentum post-transaction do not present material governance or transparency concerns at this time.

CFO Mark W Hahn sold 208,912 shares of VRNA at $13.14 on 2025-08-01; stock up 15.2% in 30 days.

Mark W Hahn, Chief Financial Officer of Verona Pharma plc, sold 208,912 shares (208.9K shares) at $13.14 on 2025-08-01, reducing his holdings by 1.6% to 12,464,968 shares (12.46M shares). The stock has since appreciated significantly—up 15.2% in 30 days and 52.4% in 90 days since the sale, indicating this transaction was poorly timed relative to subsequent price performance. Notably, his prior VRNA trade on 2025-05-02 showed similar post-sale strength, with a 90-day return of +1055.6%, and his cross-ticker track record demonstrates that stock prices have risen an average of +1158.2% in the 90 days following his sales (90d well-timed rate 0.00%), further underscoring a consistent pattern of selling before rallies. The company remains unprofitable with a net loss of $16,319,000.00 ($-16.3M) in its most recent quarter and full-year period, creating a context in which the CFO's sales deserve monitoring even as they coincide with substantial stock gains rather than declines.

General Counsel Fisher Andrew sold 80,000 shares of VRNA at $11.52 on 2025-06-16, retaining 360.0K shares post-transaction.

Fisher Andrew, General Counsel of Verona Pharma, sold 80,000 shares at $11.52 on 2025-06-16, reducing his holdings by 18.2% to 359,999 shares. The company reported $76.3M in latest quarterly revenue against a net loss of $16.3M and remains unprofitable on a full-year basis. The current stock price of $90.92 is 30-day +25.3% and 90-day +37.2% above the transaction date, suggesting the sale preceded a significant appreciation period. Prior trades in this insider's cross-ticker history show 1 prior open-market sell with a 30d return of +975.8%, indicating a pattern where his sells have been followed by gains rather than declines. This transaction represents a material disposition by a senior executive of an unprofitable biotech concern during a period of strong positive momentum, though the underlying fundamentals remain challenged by ongoing losses.

CFO Hahn Mark W sold 400,000 shares of VRNA at $11.40; stock now trades at $92.20, up 37.1% in 30 days

Mark W Hahn, CFO of Verona Pharma, sold 400,000 shares (400.0K shares) at $11.40 on 2025-06-11 for $4,560,360.00 ($4.6M), reducing his holdings to 12,278,992 shares (12.28M shares). The stock has appreciated dramatically since the transaction date, reaching $92.20 (current price) with a 30-day return of +37.1% and 90-day return of +50.2%, placing the price -0.3% from its 52-week high of $92.50. At the same ticker (VRNA), Hahn's prior two measurable sales (on 2025-05-02 and 2025-05-01) both generated positive 30-day returns of +792.9% and +807.2% respectively, indicating his prior VRNA sales preceded sharp gains, not declines. The company is unprofitable (net income $-16,319,000.00 ($-16.3M)) with latest quarterly revenue of $76,256,000.00 ($76.3M), and the stock's 50% run-up over 90 days contrasts sharply with the CFO's simultaneous reduction of his own stake.

CEO David Zaccardelli sold 400,000 shares of VRNA at $11.40 on 2025-06-11, retaining 13.19M shares post-sale in unprofitable company.

David Zaccardelli, President and CEO, sold 400,000 shares at $11.40, reducing his holdings to 13,190,168 shares while retaining substantial ownership. The company reported revenue of $76,256,000.00 in its latest quarter but posted a net loss of $-16,319,000.00 and was unprofitable over its most recent full fiscal year. Stock price has risen 37.1% in the past 30 days and 50.2% in the past 90 days, currently trading at $92.20—near its 52-week high of $92.50. Across his cross-ticker track record, Zaccardelli's sells have exhibited a 0.00% well-timed rate at the 90-day mark, indicating his prior sales have been poorly-timed (stock subsequently rose). At the same ticker, his three most recent sales on 2025-05-29, 2025-05-28, and 2025-05-27 lack measurable outcomes. The sale occurred during a period of significant stock appreciation in an unprofitable company, which may merit observation given the fundamental backdrop.

Verona Pharma CEO sells 400,000 shares ($3.7M) across 3 days at avg $9.34; stock now at $77.49

David Zaccardelli, President and CEO, executed 3 separate sales totaling 400,000 shares for $3,734,578.83 on 2025-05-27 through 2025-05-29 at prices ranging from $9.30 to $9.53. The transaction occurred at a blended average price of $9.34, while the current stock price stands at $77.49—representing a stark 730% spread between the transaction prices and today's market. Zaccardelli retained 13,590,168 shares post-transaction, reducing his holdings by 2.9%. The company is unprofitable with a net income of $-16,319,000.00 in the latest quarter, yet carries a market capitalization of $52,775,031,144.78. His prior 5 trades at Verona show mixed timing outcomes: one 2024 sale generated substantial 30-day and 90-day returns (+830.2% and +1211.1%), while more recent sales from April and May show only partial outcome visibility, with only 0 of 1 measurable prior sales well-timed at the 90-day mark.

Verona Pharma CFO Mark W Hahn sells 400,000 shares in 3 trades (May 27–29) for $3,733,944.47; stock rises to $77.49 post-sale.

Mark W Hahn, Chief Financial Officer of Verona Pharma, executed 3 separate sales totaling 400,000 shares for $3,733,944.47 (blended average $9.33) over three consecutive trading days. The stock has since appreciated significantly, trading at a 52-week high of $77.49, representing a sharp disconnect between the transaction prices ($9.33) and current valuation. Notably, his cross-ticker track record shows a well-timed sell rate of 0.00% across 20 prior sales, with an average 90-day return post-sale of +1162.7%—indicating his prior sales have been consistently poorly timed, as stocks typically rose after his exits. At Verona specifically, his one prior measurable 90-day outcome (December 2024 sale) showed +1211.0% return, reinforcing the pattern. The company remains unprofitable with net income of $-16,319,000.00 against revenue of $76,256,000.00, adding context to the divergence between insider action and market momentum.

Director Vikas Sinha sold 160,000 shares of VRNA at $9.39 for $1.5M, reducing stake by 68.2% amid unprofitable operations.

Director Vikas Sinha sold 160,000 shares (160.0K shares) at $9.39 on 2025-05-20, reducing his holding from 234,440 to 74,440 shares—a 68.2% reduction of his pre-transaction position. The sale occurs in the context of an unprofitable company: Verona Pharma reported a net income of $-16.3M over its most recent full fiscal year. The transaction price of $9.39 stands significantly below the current price of $72.69, suggesting the sale occurred during a period when the stock was trading at substantially lower valuations than today. This substantial divestiture by a director, paired with the company's ongoing losses and the historical price differential, warrants investor attention to the company's operational trajectory and the director's remaining conviction level.

General Counsel Andrew Fisher sells 80,000 VRNA shares at $8.57; stock up 22.3% in 30 days post-sale; company unprofitable.

Fisher Andrew, General Counsel, sold 80,000 shares (80.0K shares) of Verona Pharma plc at $8.57 on 2025-05-15, reducing his holdings by 18.2% from 440.0K shares to 360.0K shares. The sale occurred in a context of strong recent price momentum: the stock has risen 22.3% over the prior 30 days and is currently trading at $71.31, far above the sale price. Critically, the company remains unprofitable with a net income of $-16.3M in its most recent full fiscal year, while generating only $76.3M in quarterly revenue. The timing of a significant insider reduction—occurring well before the current price spike—suggests the transaction predates the recent momentum, making it difficult to infer conviction either way from price action alone.